Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.
about
Treatment for Lambert-Eaton myasthenic syndromeTreatment for Lambert-Eaton myasthenic syndromeThe emerging diversity of neuromuscular junction disordersOnconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brainRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesAutoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.Lambert-Eaton myasthenic syndrome without anti-calcium channel antibody: adverse effect of calcium antagonist diltiazemLong term outcome in Lambert-Eaton myasthenic syndrome without lung cancerLambert-Eaton myasthenic syndrome: evidence for calcium channel blockade.Macromolecular connections of active zone material to docked synaptic vesicles and presynaptic membrane at neuromuscular junctions of mouseCirculating T cell subsets in the Lambert-Eaton myasthenic syndrome.Congenital Lambert-Eaton myasthenic syndrome.Neuromuscular disease and calcium channels.Role of exercise in maintaining the integrity of the neuromuscular junction.Passive transfer of autoimmune autonomic neuropathy to mice.Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studiesUpdate on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridineSynaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.Respiratory muscle weakness in the Lambert-Eaton myasthenic syndromeSmall-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease.Autoimmune channelopathies of the nervous systemVoltage gated calcium channel antibody-related neurological diseasesComplete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer modelReview of evidence for loss of motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome.Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo.Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndromeCalcium channels link the muscle-derived synapse organizer laminin β2 to Bassoon and CAST/Erc2 to organize presynaptic active zones.The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinomaActive zone density is conserved during synaptic growth but impaired in aged mice.Lambert-Eaton sera reduce low-voltage and high-voltage activated Ca2+ currents in murine dorsal root ganglion neurons.Molecular mechanism of active zone organization at vertebrate neuromuscular junctions.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.The auto-antigen repertoire in myasthenia gravis.Autoantibodies in neuromuscular autoimmune disorders.Endplate contributions to the safety factor for neuromuscular transmission.Presynaptic Active Zone Density during Development and Synaptic PlasticityNeural antigen-specific autoimmune disorders.Structural and functional maturation of active zones in large synapses.
P2860
Q24234103-D47D0C5F-EB28-46AD-9791-F87CAC82FFEAQ24246913-832C33D2-B921-437F-8838-7D95F48FACA7Q24595915-3D6EC38B-7F8D-4AED-B0B9-3D2F53E64C1AQ24602799-A4D392D4-41B7-4B8A-9C2B-1BB86B1E0C1BQ26864907-D82160F4-8815-4E96-807D-B81365A07CE6Q28264405-853D166B-9123-4ECC-9C27-1CB76D7CDAECQ28343201-C9E5CA7A-6DF0-4054-95D5-BFCB431B1E56Q28346582-E94123FB-5CF6-442D-A794-7AC33EC60D95Q30457343-A09E2E53-D845-4AC5-8B4E-D75B98EA3E7BQ33410405-245D398D-443A-472A-B3AB-CC0B333A8DDCQ33621091-3108F489-D60E-4288-86F1-61D7A67F00E8Q33628143-1DB43C6F-0114-437F-981B-B390E255CF61Q33733240-06A3802D-E4C6-4C5C-BCB2-F45B1916BA99Q33862222-368B6107-9F57-4709-B972-B47EB7B2D382Q33938477-A6FD416B-4251-4D14-BE3A-031494F6DEDAQ34127075-AFD07A6C-06D3-4268-B2E2-9651FB89D5C2Q34206472-E79714F6-F659-4B4D-BCB2-5D5DD1DBE00AQ34437216-D24EBD0A-DE5E-4D5A-8B91-3E7598E83D39Q34669734-9709690A-0126-49B0-9DCD-63032F83F314Q34826137-F2AFC53F-073C-44CF-95C4-5265A3DF8255Q34968165-06024E54-6727-461C-A9ED-53C9FD0DEAB6Q35151881-595E8AFC-6C46-486C-A922-FE0574749AF7Q35179343-73772F34-86A4-4336-84EB-29C8D11FE54CQ35205835-0BA510F5-BAC3-4BCA-B4D8-51536ACEEBC8Q35242214-0D89ED07-5AA1-427E-A96D-8E53AB81BDDEQ36443756-DA4AB4B9-B6BA-43C1-A75E-BBAF9D4DEB9FQ36497513-14E78DED-30BC-4A85-840E-36219D7D7177Q36938303-304AFA5A-2088-46D2-BE3E-348765B49F8AQ37044607-0DCE89D6-8E24-4149-AF3B-29372D449CCFQ37054967-6E3426EC-3805-4FBE-999A-B22459369563Q37063488-9A0D1E57-8AD5-46E9-B947-6293CC5ECEF3Q37391686-261D3ED3-B561-4F4A-9612-3EC3BBEF3298Q37472670-E653C53B-2412-4E30-8511-54A865BB8C80Q37620483-2A3A5C4A-62B6-442E-8409-45E29FD4C7FCQ37727984-D352C526-28B0-45C5-ADB4-58E7C4DDBF1AQ37754738-BFB0E148-CA3D-43C0-82D7-EAD02FE0435CQ37958824-31BFAB75-C990-4000-99A2-1DDF11733301Q37996017-CA7AC500-E519-4B18-9512-258BD1646A8FQ38020960-93391AD6-3781-437B-B99B-8360D6EBE999Q38044850-B771FA62-D6EA-4E44-BC7C-81CD0678EAFF
P2860
Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1983
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@en
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@nl
type
label
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@en
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@nl
prefLabel
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@en
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@nl
P2093
P2860
P356
P1476
Passive transfer of Lambert-Ea ...... ynaptic membrane active zones.
@en
P2093
P2860
P304
P356
10.1073/PNAS.80.24.7636
P407
P577
1983-12-01T00:00:00Z